Search Results 701-710 of 18669 for hepatitis

1. Infectious Diseases - Expertise and rankings - Mayo Clinic

   Specialty areas include bacteriology, hepatitis/ HIV , infectious disease serology, initial processing/media, mycology/mycobacteriology, parasitology, vector- ...

2. Combination Therapy of Acalabrutinib, Venetoclax and Durvalumab to Treat Richter Transformation - Mayo Clinic

   Hepatitis B or C serologic status: Hepatitis B surface antigen and hepatitis B PCR positive will be excluded; Hepatitis B core antibody (anti-HBc) positive ...

3. A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 in Amyotrophic Lateral Sclerosis (ALS) Patients - Mayo Clinic

   Current hepatitis B infection (defined as positive for hepatitis B surface antigen [HBsAg] and/or total hepatitis B core antibody [anti-HBc]). Participants ...

4. Belantamab, Lenalidomide, and Daratumumab for Newly-diagnosed Multiple Myeloma - Mayo Clinic

   Note: Hepatitis RNA testing is optional and participants with negative Hepatitis C antibody test are not required to also undergo Hepatitis C RNA testing.

5. LS138D, Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma - Mayo Clinic

   Hepatitis B surface antigen (HBsAg) positive; HBsAg negative, anti-hepatitis B surface antibody (HBs) positive and/or anti-hepatitis B core antibody (HBc) ...

6. Unexplained weight loss Causes - Mayo Clinic

   Alcoholic hepatitis · Amputation and diabetes · Amyloidosis · Angina · Anorexia nervosa · Antidepressant withdrawal: Is there such a thing? Antidepressants and ...

7. Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects - Mayo Clinic

   disease, viral hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, Wilson's disease, hemochromatosis, alpha-1 ...

8. A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy - Mayo Clinic

   Patients who are HBsAg negative and hepatitis B core antibody positive with no detectable hepatitis B virus (HBV) DNA will be allowed into the study but will ...

9. ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies - Mayo Clinic

   Participation eligibility · Subjects who are hepatitis B core antibody (anti-HBc) positive and who are surface antigen negative will need to have a negative ...

10. Zelalem Temesgen, M.D. - Doctors and Medical Staff - Mayo Clinic

    National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention PARTNERS IN PUBLIC HEALTH IMPROVEMENT (GROUP)Centers for Disease Control and ...